You are viewing: Mexico Oral Proteins & Peptides Market analysis

The Mexico Oral Proteins & Peptides Market was valued at $43.1 Million in 2025 and projected to reach to $88 Million by 2030, representing a compound annual growth rate of 15.3%. Mexico's oral proteins and peptides market is positioned for sustained growth as healthcare stakeholders prioritize innovative therapeutic solutions and patient-centric delivery mechanisms.

Mexico Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Mexico Oral Proteins & Peptides Market Trends and Insights

  • This 15.3% compound annual growth rate reflects Mexico's increasing adoption of advanced pharmaceutical delivery systems and rising demand for innovative therapeutic solutions.
  • Mexico's healthcare sector is progressively embracing oral peptide formulations as alternatives to injectable treatments, driven by patient preference for non-invasive administration routes and improved bioavailability technologies. The Mexican market benefits from growing healthcare expenditure, expanding middle-class populations, and enhanced regulatory frameworks supporting biopharmaceutical innovation.
  • Mexico's strategic position within Latin America positions it as a key hub for oral protein and peptide development and commercialization.
  • Between 2025 and 2030, Mexico is expected to see accelerated investment in research and development, coupled with increased collaboration between domestic and international pharmaceutical manufacturers seeking to capitalize on the region's untapped potential..

Key Market Statistics

  • CAGR (2025-2030) 15.3% CAGR
  • Market Size, 2025 ~USD 43.1 Million
  • Forecast, 2030 ~USD 88 Million
  • Country Mexico

Mexico Oral Proteins & Peptides Market Overview

Market Valuation Growth :

Mexico's oral proteins and peptides market is valued at $43.1 million in 2025, with projections to reach $88.0 million by 2030, representing a 15.3% CAGR over the forecast period.

Advanced Delivery System Adoption :

Mexican healthcare providers are increasingly adopting oral peptide formulations and advanced pharmaceutical delivery systems, driven by improved bioavailability technologies and patient preference for non-invasive administration routes.

Therapeutic Innovation Pipeline :

Mexico's pharmaceutical sector is expanding its focus on innovative oral peptide therapeutics for chronic disease management, including diabetes, cardiovascular conditions, and metabolic disorders, addressing significant unmet medical needs.

Healthcare Infrastructure Development :

Strengthening healthcare infrastructure and increased investment in pharmaceutical R&D across Mexico are creating favorable conditions for the commercialization and adoption of oral protein and peptide-based therapies.

Mexico Oral Proteins & Peptides Market Dynamics

  • The 15.3% CAGR reflects Mexico's commitment to modernizing its pharmaceutical landscape and improving treatment accessibility across diverse patient populations.
  • Regulatory support and growing healthcare expenditure are expected to accelerate market penetration. The forecast period through 2030 will be characterized by increased clinical adoption, expanded manufacturing capabilities, and strategic partnerships between Mexican healthcare institutions and international pharmaceutical companies.
  • Rising prevalence of chronic diseases, coupled with growing awareness of oral peptide therapies, will drive demand.
  • Mexico's position as a regional healthcare hub positions it favorably for market expansion and technology transfer initiatives..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Mexico's oral proteins & peptides market is valued at $43.1 million in 2025 and projected to double to $88.0 million by 2030, representing a 15.3% CAGR.
    • Mexico is emerging as a strategic Latin American hub for oral peptide formulations, driven by patient demand for non-invasive delivery alternatives.
    • Growing healthcare infrastructure and regulatory support in Mexico are accelerating biopharmaceutical innovation and market penetration.
    • Mexico's expanding middle class and rising healthcare expenditure are key drivers fueling market growth through 2030.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Mexico Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS54.584.198.6115.6136161188.9221.817.6
    HOSPITALS & SPECIALTY CLINICS15.423.326.730.535.140.546.453.114.8
    LONG-TERM CARE FACILITIES22.434.440.146.754.664.174.887.316.8
    TOTAL92.3141.8165.3192.9225.7265.6310.1362.217

    Target Audience

    • Pharmaceutical Manufacturers : Manufacturers need Mexico-specific market data to evaluate market entry strategies, assess competitive positioning, and identify opportunities for oral protein and peptide product launches in this growing market.
    • Healthcare Investors & PE Firms : Investment professionals require detailed Mexico market analysis to evaluate portfolio opportunities, assess growth potential, and make informed capital allocation decisions in the oral therapeutics sector.
    • Medical Device & Biotech Companies : Biotech firms need Mexico-focused insights to understand delivery system adoption rates, regulatory pathways, and partnership opportunities for oral peptide formulation technologies.
    • Healthcare Consultants & Advisors : Consultants require granular Mexico market data to provide strategic recommendations to clients on market entry, competitive positioning, and growth strategies in oral proteins and peptides.
    • Government & Healthcare Policy Makers : Mexican healthcare officials and policymakers need market intelligence to inform pharmaceutical policy, healthcare infrastructure investments, and regulatory frameworks supporting oral peptide innovation.

    Key Companies in the Mexico Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Market-Specific Growth Projections : Access detailed Mexico-focused forecasts showing 15.3% CAGR through 2030, enabling accurate business planning and investment decisions tailored to this high-growth Latin American market.
    • Competitive Landscape Intelligence : Understand Mexico's unique competitive dynamics, local pharmaceutical players, and market entry strategies specific to Mexican regulatory requirements and healthcare infrastructure.
    • Regulatory & Reimbursement Insights : Gain critical intelligence on Mexico's pharmaceutical approval pathways, reimbursement mechanisms, and healthcare policy frameworks affecting oral protein and peptide commercialization.
    • Regional Market Positioning : Benchmark Mexico's 15.3% CAGR against global 22.1% growth to identify localized opportunities and develop targeted strategies for this emerging market segment.
    • Investment & Partnership Opportunities : Identify high-potential partnerships, distribution channels, and investment opportunities within Mexico's expanding oral peptide ecosystem and healthcare infrastructure development initiatives.

    Frequently asked questions

    What is the current market size of oral proteins and peptides in Mexico?

    Mexico's oral proteins and peptides market was valued at $43.1 million in 2025 and is expected to grow to $88.0 million by 2030.

    What is the projected growth rate for Mexico's oral proteins and peptides market?

    Mexico's oral proteins and peptides market is projected to grow at a compound annual growth rate (CAGR) of 15.3% from 2025 to 2030.

    What factors are driving growth in Mexico's oral proteins and peptides market?

    Key drivers include increasing healthcare expenditure, growing middle-class populations, patient preference for non-invasive delivery routes, improved bioavailability technologies, and enhanced regulatory frameworks supporting biopharmaceutical innovation in Mexico.

    Why is Mexico important for the Latin American oral proteins and peptides market?

    Mexico's strategic geographic position, expanding healthcare infrastructure, regulatory support, and growing pharmaceutical investment make it a key hub for oral peptide development and commercialization within Latin America.

    How much is Mexico's oral proteins and peptides market expected to grow by 2030?

    Mexico's market is expected to more than double from $43.1 million in 2025 to $88.0 million by 2030, representing a total growth of approximately 104% over the five-year forecast period.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status